Theraclion announced on Thursday the successful completion of its €8.4 million capital increase, designed to secure its financial visibility over the next two years.

The company, which has developed a robotic platform for non-invasive ultrasound therapy, reports that it has issued 14.5 million new shares with warrants (ABSA), each with a par value of €0.577.

Theraclion notes that the Chinese pharmaceutical group Furui has subscribed to 10.4 million ABSA through its French subsidiary, representing a subscription of six million euros.

In total, Furui has invested seven million euros, taking into account the one million euros through the exercise of warrants conditional on the achievement of milestones.

As part of their strategic partnership, Theraclion and Furui plan to work together to establish production capacity in China for Sonovein (for varicose veins) and Echopulse (for breast fibroadenomas and thyroid nodules).

The licensing of its technologies and the authorization to use its trademarks in China will trigger a payment of three million euros linked to the achievement of specific objectives.

Overall, the capital increase, the full exercise of the warrants and the payment of the licensing fees represent a total financing of 12.7 million euros, of which 8.4 million euros were acquired today.

Copyright (c) 2023 CercleFinance.com. All rights reserved.